| 蔡 君,马 红,朱涤潮.转移性结直肠癌贝伐单抗治疗中高血压的发生情况及客观有效率[J].肿瘤学杂志,2013,19(11):854-857. |
| 转移性结直肠癌贝伐单抗治疗中高血压的发生情况及客观有效率 |
| Bevacizumab-induced Hypertension and Its Treatment Response in Metastatic Colorectal Cancer |
| 投稿时间：2013-09-15 |
| DOI：10.11735/j.issn.1671-170X.2013.11.B006 |
|
 |
| 中文关键词: 结直肠肿瘤 靶向治疗 贝伐单抗 高血压 肿瘤转移 |
| 英文关键词:colorectal neoplasms targeted therapy bevacizumab hypertension neoplasm metastasis |
| 基金项目: |
|
| 摘要点击次数: 2376 |
| 全文下载次数: 789 |
| 中文摘要: |
| 摘 要：［目的］ 观察贝伐单抗治疗转移性结直肠癌中高血压的发生情况，评价其对贝伐单抗疗效的预测价值。［方法］ 回顾性分析贝伐单抗联合化疗治疗的转移性结直肠癌患者中，不良反应高血压的发生情况。根据是否发生贝伐单抗相关性高血压把患者分为两组，比较两组疾病有效率(RR)情况。［结果］ 64例患者中完全缓解（CR）5例（7.8%），部分缓解（PR）31例（48.4%）。使用贝伐单抗出现高血压的患者为15例，CR+PR为12例，RR为80.0%，而使用贝伐单抗未出现高血压的患者为49例，其中CR+PR为24例，RR为49.0%。两组比较差异无统计学意义（P=0.034）. ［结论］ 高血压为贝伐单抗治疗转移性结直肠癌中常见不良反应，高血压的出现有可能成为判断其疗效的较好的预测因子。 |
| 英文摘要: |
| Abstract:［Purpose］ To investigate the occurrence of hypertension induced by bevacizumab in the treatment for metastatic colorectal cancer (mCRC) and to evaluate its value in predicting efficacy of bevacizumab.［Methods］ The occurrence of bevacizumab-related hypertension in mCRC patient treated with bevacizuma combined with chemotherapy was analyzed retrospectively. Patients were divided into two groups according to the occurrence of bevacizumab-induced hypertension or not. And short term recent response rates of the two groups were compared. ［Results］ Of 64 cases in the 2 groups，5 cases (7.8%) were complete response(CR)，31 cases(48.4%)，partial response (PR). There were 15 cases complicated with bevacizumab-induced hypertension，with CR+PR in 12 cases(RR 80.0%)， and 49 cases without bevacizumab-induced hypertension，with CR+PR in 24 cases(RR 49.0%). There was significant difference between the two groups(P=0.034). ［Conclusion］Hypertension is the common toxicity in mCRC patients treated with bevacizumab. Bevacizumab-induced hypertension might be the potential factor for predicting the effect. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |